ModifiedUnitedHealthcarePolicy CS165ID.C

Genetic Testing for Neurological Disorders (for Idaho Only)

Policy governing coverage and medical necessity criteria for multi-gene (>=5 genes) genetic testing for neurological disorders for members in Idaho, including Idaho Medicaid Plus plans, and guidance for ordering clinicians and documentation.

Policy Summary

PayerUnitedHealthcare

PolicyGenetic Testing for Neurological Disorders (for Idaho Only)

Policy CodePolicy CS165ID.C

Change TypeCriteria revisioncode removalsdefinition updates

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionOrder multi-gene targeted panels (>=5 genes) only when a relevant specialist documents that results are expected to directly impact medical management and records support medical necessity.

SourceLink

POLICY UPDATE CHANGES

Multi-gene Targeted Panel testing (five or more genes) for neurological disorders is proven and medically necessary when specific clinical and ordering criteria are met.

Comprehensive panel tests intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders are unproven and not medically necessary.

Removed CPT codes 0417U, 81440, 81460, and 81465.

Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage and must support medical necessity.

Added definitions for Ataxia, Comprehensive Panel, Congenital Myopathy, Metabolic Myopathy, and Targeted Panel; removed definitions for CGH, NMD, NGS, and VUS.

>=5Threshold for panels

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

IdahoState applicability

Not coveredComprehensive panels stance

52.9%Highest reported yield

Coverage Criteria

Medically necessary multi-gene targeted panel criteria

Multi-gene Targeted Panel testing (five or more genes) for neurological disorders is proven and medically necessary when ALL of the following criteria are met:

Panel medical necessity criteria: The individual to be tested displays signs or symptoms of a heritable neurological disorder and the results are expected to directly impact medical management of that disorder; and the test is ordered by a medical geneticist, developmental pediatrician, or adult or pediatric neuromuscular or neurogenetics specialist; and the test is intended to establish a genetic cause for any one of: Congenital or Metabolic Myopathy; Ataxia; Peripheral neuropathy; Hereditary spastic paraplegia; Muscular dystrophy.>= 5 genes

From policy Non‑State‑Specific Criteria (multi‑gene targeted panels >=5 genes)

Multi-gene Targeted Panel — Medically Necessary — Covered when ALL of the following are met

Covered when ALL of the following are met

Multi-gene panel coverage criteria: The individual displays signs or symptoms of a heritable neurological disorder; and test results are expected to directly impact medical management; and the test is ordered by or in consultation with a medical geneticist, developmental pediatrician, or adult or pediatric neuromuscular or neurogenetics specialist; and the test is intended to establish a genetic cause for one of the specified diagnostic categories (e.g., congenital or metabolic myopathy, ataxia, hereditary spastic paraplegia, muscular dystrophy).multi-gene panels >=5 genes

From Policy History/Revision Information

Not medically necessary — Comprehensive panels

Not medically necessary: Comprehensive panels: Comprehensive Panel tests intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders are unproven and not medically necessary due to insufficient evidence of efficacy.

Policy explicitly designates comprehensive panels as not medically necessary

Comprehensive / Multi-category Panels — Not Medically Necessary

Comprehensive multi-category panels: Comprehensive panel tests intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders are unproven and not medically necessary due to insufficient evidence of efficacy.

Policy History/Revision Information

Comprehensive Panel tests — Not medically necessary when:

Not medically necessary when:

Comprehensive panels: The panel evaluates multiple genes across multiple clinically distinct neurological disorder categories (i.e., a ‘comprehensive’ or multi‑category panel).

Deemed unproven and not medically necessary due to insufficient evidence of efficacy; see policy notes that WES/WGS are addressed by a separate policy.

Comprehensive multi-gene panels that evaluate genes across multiple, clinically distinct neurological disorder categories are designated in this policy as unproven and not medically necessary. The policy states that such panels lack sufficient evidence of efficacy to support coverage and therefore are excluded from medical necessity coverage determinations for neurological genetic testing.[[3]][[36]]

This policy explicitly states that comprehensive panels spanning multiple clinically distinct neurological disorder categories are unproven and not medically necessary. Whole Exome and Whole Genome Sequencing are handled under a separate UnitedHealthcare policy and do not change the noncoverage designation for broad, multi-category panels under this policy.[[36]][[3]]

Exclusion summary: tests described as comprehensive panels intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders are excluded from coverage as not medically necessary due to insufficient evidence of clinical benefit. Providers ordering genetic testing should select targeted panels that match the specific diagnostic category and clinical presentation rather than broad, multi-category assays.[[36]][[3]]

Policy history note: earlier revisions removed definitions for certain terms. In particular, the policy history documents removal of the definitions for Comparative Genomic Hybridization (CGH) and Neuromuscular Disorders (NMD) from the definitions section.[[78]][[109]]

Covered Indications

Establishing a genetic cause for congenital or metabolic myopathy, ataxia, peripheral neuropathy, hereditary spastic paraplegia, or muscular dystrophy when results will directly impact medical management.

Covered indication — genetic cause for listed disorders: Testing to establish a genetic cause for congenital or metabolic myopathy, ataxia, peripheral neuropathy, hereditary spastic paraplegia, or muscular dystrophy when results will directly impact medical management.

Covered Indication from policy Non‑State‑Specific Criteria

Suspected heritable neurological disorder with phenotypes such as congenital or metabolic myopathy, ataxia, hereditary spastic paraplegia, muscular dystrophy — test must directly impact management and be ordered by/with specialist

Suspected heritable neurological disorder criteria: Suspected heritable neurological disorder with phenotypes such as congenital or metabolic myopathy, ataxia, hereditary spastic paraplegia, or muscular dystrophy; the test must be expected to directly impact medical management and be ordered by or in consultation with a medical geneticist, developmental pediatrician, or adult/pediatric neuromuscular or neurogenetics specialist.>= 5 genes

Coding / Applicable Codes

Procedure codes referencedmixed

0216U	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants.
0217U	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants
81448	Hereditary peripheral neuropathies (e.g., Charcot-Marie-Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (e.g., BSCL2 , GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1 ).
81479	Unlisted molecular pathology procedure

Removed CPT CodesCPTNot Covered

0417U	CPT code removed (0417U).
81440	CPT code removed (81440).
81460	CPT code removed (81460).
81465	CPT code removed (81465).

Removed CPT codesCPTNot Covered

0417U	CPT code removed (no description provided in excerpt)
81440	CPT code removed (no description provided in excerpt)
81460	CPT code removed (no description provided in excerpt)
81465	CPT code removed (no description provided in excerpt)

Removed CPT CodesCPTNot Covered

0417U	CPT code removed (0417U) per Policy History
81440	CPT code removed (81440) per Policy History
81460	CPT code removed (81460) per Policy History
81465	CPT code removed (81465) per Policy History

Removed CPT CodesCPTNot Covered

0417U	Removed CPT code
81440	Removed CPT code
81460	Removed CPT code
81465	Removed CPT code

Applicable Codes — removedCPTNot Covered

0417U	CPT code removed (as listed in policy history)
81440	CPT code removed (as listed in policy history)
81460	CPT code removed (as listed in policy history)
81465	CPT code removed (as listed in policy history)

Removed CPT CodesCPTNot Covered

0417U	CPT code removed per policy history
81440	CPT code removed per policy history
81460	CPT code removed per policy history
81465	CPT code removed per policy history

Applicable Codes — RemovedCPTNot Covered

0417U	CPT code removed
81440	CPT code removed
81460	CPT code removed
81465	CPT code removed

Panel gene count — threshold for multi-gene targeted panels considered in policy

Panel gene count>= 5 genes

ContextPolicy applies to multi-gene targeted panels for neurological disorders (panels of five or more genes).

Example code requiring >=5 genes81448 description notes panel must include sequencing of at least 5 peripheral neuropathy-related genes.

Specific CPT codes (noted historically as 0417U, 81440, 81460, and 81465) have been removed from the policy’s Applicable Codes list. Consult the full, current policy to determine the present coverage or authorization status for these procedure codes before submitting claims or prior authorization requests.[[59]][[141]]

Policy notation: CPT codes 0417U, 81440, 81460, and 81465 were removed from the Applicable Codes list in the policy history. These codes are no longer listed as applicable under this policy segment and should not be used for coverage determinations without confirming current guidance in the policy.[[141]][[159]]

Provider Actions and Documentation Requirements

Prior Authorization

Prior authorization: Prior authorization may be required for multi‑gene targeted panel testing (no specific codes listed in this section). Providers should obtain prior authorization when applicable and verify current authorization requirements before ordering.

Prior authorization requirement applies to multi-gene targeted panels (≥5 genes) when meeting medical necessity criteria.

Denial Risk

Applicable Codes Removed — Denial Risk

Applicable codes removed: Certain CPT codes have been removed from the Applicable Codes list. Claims submitted with removed CPT codes (e.g., 0417U, 81440, 81460, 81465 as noted in policy history) may be denied or require updated coding prior to submission.

Removed CPT codes noted in policy history: 0417U, 81440, 81460, 81465.
Claims using removed codes may be denied; verify coding before claim submission.

Not Covered / Exclusions

Not covered: The policy states that comprehensive panels intended to evaluate multiple genes across multiple clinically distinct neurological disorder categories are not covered. Coverage is limited to targeted multi-gene panels that meet the policy’s specific clinical and ordering criteria (e.g., test intended to establish a genetic cause for specified diagnostic categories and ordered by an appropriate specialist).[[3]][[36]]

Policy explicit statement: Comprehensive panels that aggregate genes from more than one clinically distinct neurological category are designated as not medically necessary and therefore not covered under this policy. Providers should use disorder-specific targeted panels when the testing is intended to address a single diagnostic category.[[36]][[3]]

Tests billed with CPT codes 0417U, 81440, 81460, or 81465 are not applicable under this policy excerpt because these codes were removed from the Applicable Codes list in policy history. Confirm current acceptable codes in the full policy prior to billing.[[141]][[59]]

This policy segment explicitly removed CPT codes 0417U, 81440, 81460, and 81465 from the list of applicable codes in multiple revision entries; as a result, services billed under these codes are not covered per the policy history and should not be submitted without verification of current coding guidance.[[159]][[200]]

Tests billed with CPT codes 0417U, 81440, 81460, or 81465 are no longer listed as applicable procedure codes in the policy’s Applicable Codes section and therefore are not covered under this policy segment unless a later policy revision reinstates or replaces them. Always verify the current policy before claim submission.[[254]][[213]]

Definitions

Ataxia — definition

DefinitionAtaxia: A condition of the nervous system that causes loss of control of muscle movement and coordination.

Clinical noteAtaxia can be a symptom of another condition or occur in isolation (NINDS).

Policy usageListed as one of the diagnostic categories for which multi-gene panels (>=5 genes) may be medically necessary.

Comprehensive Panel — definition

DefinitionComprehensive Panel: An assay that simultaneously tests more than one gene associated with a variety of conditions, symptoms, or non-overlapping clinical presentations.

Policy stanceComprehensive panels spanning multiple clinically distinct neurological categories are deemed unproven and not medically necessary.

Background

Background overview: genetic testing for neurological disorders ranges from single‑variant or single‑gene tests up to multi‑gene panels and broader approaches such as Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS). This policy addresses multi‑gene targeted panels of five or more genes (>=5 genes) and emphasizes interpretation considerations and appropriate specialist ordering; WES/WGS are governed by a separate policy for Idaho. Results from appropriately selected genetic testing can inform diagnosis, prognosis, and management for heritable neurological conditions.[[3]][[36]]

Policy History / Revision Information

2026-05-01Title change and substantive criteria updateLatest

Policy retitled and revised with new multi-gene targeted panel criteria specifying symptomatic individuals, expected direct impact on management, specialist ordering requirements, and diagnostic categories (e.g., congenital or metabolic myopathy, ataxia, hereditary spastic paraplegia, muscular dystrophy).

2026-05-01Definitions added

Added definitions for Ataxia, Comprehensive Panel, Congenital Myopathy, Metabolic Myopathy, and Targeted Panel in the policy history.

Policy Summary

PayerUnitedHealthcare

PolicyGenetic Testing for Neurological Disorders (for Idaho Only)

Policy CodePolicy CS165ID.C

Change TypeCriteria revisioncode removalsdefinition updates

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionOrder multi-gene targeted panels (>=5 genes) only when a relevant specialist documents that results are expected to directly impact medical management and records support medical necessity.

SourceLink

On This Page

From Policy History/Non‑State‑Specific Criteria

Items listed in Summary of Changes (Comprehensive Panel, Congenital Myopathy, Metabolic Myopathy, Targeted Panel) — referenced in policy history

Summary of Changes items: Items listed in the Summary of Changes include: Comprehensive Panel; Congenital Myopathy; Metabolic Myopathy; Targeted Panel — referenced in policy history entries.

Policy History/Revision Information (Summary of Changes)

Metabolic myopathy mention in summary of changes (coverage context not present in excerpt)

Metabolic myopathy mention: Metabolic myopathy appears in the policy history Summary of Changes entries; the excerpt does not provide additional coverage details in this segment.

Policy History/Revision Information

Targeted genetic panel mention in summary of changes (coverage context not present in excerpt)

Targeted panel mention: ‘Targeted Panel’ is referenced in the Summary of Changes entries in policy history; no additional coverage context is provided in this excerpt.

Policy History/Revision Information

References to policy updates related to NGS and VUS (policy-history mentions)

NGS and VUS policy update references: Policy history entries reference Next Generation Sequencing (NGS) and Variant of Unknown Significance (VUS) in Summary of Changes and revision notes; this excerpt documents those references but does not add new operational criteria.

Policy History/Revision Information

Billing Rule

Verify Coding and Authorization

Update prior authorization codes and verify coding/prior authorization: Providers must verify current acceptable CPT codes and any prior authorization requirements following code removals or policy updates. The Applicable Codes list in this policy is reference only and may not be exhaustive.

Verify current CPT codes and prior authorization portals or payer resources before ordering or billing.
Inclusion of a code in the policy does not guarantee coverage or payment.

Note

Comprehensive Panels — Ordering Guidance

Comprehensive panels that evaluate multiple, clinically distinct neurological disorder categories are considered unproven and not medically necessary. Ordering comprehensive panels intended to evaluate multiple distinct disorder categories should be avoided unless specific clinical criteria support medical necessity.

Comprehensive panels intended to evaluate multiple categories of clinically distinct neurological disorders = not medically necessary.
Whole Exome and Whole Genome Sequencing are addressed in a separate policy (Whole Exome and Whole Genome Sequencing (Non‑Oncology Conditions) — Idaho Only).

Prior Authorization

Specialist Ordering Requirement

Specialist ordering requirement: Multi‑gene targeted panel tests (≥5 genes) must be ordered by, or in consultation with, an appropriate specialist — medical geneticist, developmental pediatrician, or adult/pediatric neuromuscular or neurogenetics specialist.

Ensure ordering clinician meets specialist requirement or documents consultation in the medical record before testing.

Documentation Required

Medical Records Documentation Requirements

Medical records documentation: Medical records must contain legible documentation that fully supports medical necessity, including relevant history, physical examination, and results of pertinent diagnostic tests or procedures. Documentation may be requested to assess whether the member meets clinical criteria and should be maintained in the patient's record and made available upon request. Insufficient or illegible documentation may result in requests for records or denial.

Documentation should include history, exam findings, diagnostic testing, and rationale for how results would directly impact medical management.
Requests may be denied if records do not document clinical indications, history, exam, or diagnostic testing supporting medical necessity.

Documentation Required

NGS and VUS — Documentation Note

NGS, VUS, and documentation notes: Next‑generation sequencing (NGS) techniques and variants of unknown significance (VUS) are referenced in the policy history; documentation expectations specific to NGS/VUS are not detailed in this section. Providers should include interpretation and clinical correlation in the record when reporting VUS findings.

Policy history references VUS and NGS; however, explicit documentation requirements for VUS are not specified here.
Include laboratory interpretation and clinical correlation in documentation when available.

Note

Policy History / Revision Notes

Policy history and limitations: This section contains policy history and revision information noting title changes, additions to criteria, additions/removals of definitions, and applicable code removals. The policy history does not provide exhaustive, actionable prior authorization code lists in this segment — providers must consult current payer resources for up‑to‑date authorization and coding requirements.

Policy history documents removal of certain CPT codes and revisions to coverage rationale and documentation language.
No explicit step therapy requirements or detailed prior authorization code lists are present in this segment.

ContrastDiffers from Targeted Panel which focuses on genes associated with a specific condition or symptom.

Targeted Panel — definition

DefinitionTargeted Panel: A curated assay that simultaneously tests more than one gene associated with a condition; may include multiple genes for one specific genetic condition or multiple genes associated with a symptom or non-specific clinical presentation.

Clinical scopeIntended to evaluate genes related to a specific phenotype or symptom rather than multiple distinct disorder categories.

Relation to policyMulti-gene Targeted Panels (>=5 genes) are the focus of the medically necessary criteria when ordered appropriately.

WES / WGS — definition

WES definitionWhole Exome Sequencing (WES): DNA analysis of the exome — the protein-coding regions (approximately 1% of the genome).

WGS definitionWhole Genome Sequencing (WGS): Determines the sequence of all nucleotides in a person's entire DNA, including coding and non-coding regions.

Policy noteWES and WGS are addressed under a separate UnitedHealthcare medical policy (Non-Oncology Conditions) for Idaho.

Ataxia — definition added in policy (revision)

Definition addedAtaxia: Added to policy definitions (loss of control of muscle movement and coordination).

Revision contextPart of policy history: definitions for Ataxia, Comprehensive Panel, Congenital Myopathy, Metabolic Myopathy, and Targeted Panel were added.

Documentation impactAdded definition supports clarity for coverage criteria referencing ataxia as an indication.

Comprehensive Panel — definition added in policy (revision)

Definition addedComprehensive Panel: Added to policy definitions as an assay testing multiple genes associated with a variety of conditions or non-overlapping clinical presentations.

Policy effectPolicy explicitly designates comprehensive multi-category panels as unproven and not medically necessary.

Revision noteListed in Summary of Changes among other newly added definitions.

Congenital Myopathy — definition added in policy (revision)

Definition addedCongenital Myopathy: Abnormality affecting muscle development, typically present at birth or early infancy; examples include central core disease, centronuclear myopathy, nemaline myopathy.

Clinical featuresMay present with muscle weakness, hypotonia, and respiratory distress.

Policy usageListed as one of the diagnostic categories for which multi-gene targeted panels may be medically necessary.

Metabolic Myopathy — definition added in policy (revision)

Definition addedMetabolic Myopathy: An abnormality from inborn errors of metabolism (e.g., glycogen storage diseases, fatty acid metabolism defects) characterized by muscle cramps, exercise intolerance, and progressive weakness.

ExamplesIncludes glycogen storage diseases and fatty acid metabolism defects.

Policy usageNamed among diagnostic categories for which targeted multi-gene testing may be medically necessary when management will be impacted.

Targeted Panel — definition added in policy (revision)

Definition addedTargeted Panel: Added in policy as a curated assay testing multiple genes associated with a specific condition or symptom/non-specific clinical presentation.

DistinctionEmphasizes targeted panels are focused and differ from comprehensive multi-category panels which are considered unproven.

Policy linkageTargeted panels of >=5 genes are addressed in the medical necessity criteria when ordered by appropriate specialists.

Comparative Genomic Hybridization (CGH) — definition removed from policy

Definition removedComparative Genomic Hybridization (CGH) — removed from policy definitions per Summary of Changes.

Revision noteCGH listed among definitions removed in Policy History/Revision Information entries.

ImpactCGH no longer appears in the policy's definitions section (see policy history).

Neuromuscular Disorders (NMD) — definition removed from policy

Definition removedNeuromuscular Disorders (NMD) — removed from policy definitions per Summary of Changes.

Revision noteNMD listed among definitions removed in Policy History/Revision Information entries.

ContextAlthough removed as a formal definition, NMD-related coverage content remains addressed elsewhere in the policy and history.

Next Generation Sequencing (NGS) — definition removed from policy

Definition removedNext Generation Sequencing (NGS) — removed from policy definitions per Summary of Changes.

Policy noteNGS remains referenced in policy history and clinical evidence sections though the formal definition was removed.

DocumentationSee Policy History entries noting removal of NGS definition.

Variant of Unknown Significance (VUS) — definition removed from policy

Definition removedVariant of Unknown Significance (VUS) — removed from policy definitions per Summary of Changes.

Policy noteVUS is referenced in revision summaries and evidence discussion but the formal definition was removed from the definitions list.

Documentation implicationPolicy history references VUS-related changes; providers should follow documentation guidance when interpreting VUS in testing reports.

Removed definitions — CGH, NMD, NGS, VUS referenced as removed in policy history

Definitions removedComparative Genomic Hybridization (CGH); Neuromuscular Disorders (NMD); Next Generation Sequencing (NGS); Variant of Unknown Significance (VUS) — all noted as removed in policy history.

SummaryPolicy History/Revision Information lists these four definitions as removed in recent revisions.

Action for providersBe aware these terms are referenced in history but are no longer present as formal definitions in the current policy document.

VUS — referenced as topic in policy revisions (no formal def in excerpt)

Reference onlyVUS is referenced as a topic in policy revision summaries but no formal definition is provided in the excerpt.

Revision contextSummary of Changes entries include Variant of Unknown Significance (VUS) as a changed topic.

Provider implicationWhile VUS is discussed in policy history, specific operational guidance or a formal definition is not present in these chunks.

Removed definitions for Comparative Genomic Hybridization (CGH), Neuromuscular Disorders (NMD), Next Generation Sequencing (NGS), and Variant of Unknown Significance (VUS).

2026-05-01Documentation requirement clarified

Clarified that medical records documentation supporting medical necessity must be legible, maintained in the patient record, and made available upon request.

2026-05-01Applicable codes updated - removals

Removed CPT/HCPCS codes 0417U, 81440, 81460, and 81465 from the policy's applicable codes list; these codes should no longer be used for coverage or prior authorization under this policy.

Summary of Changes (policy history) includes mention of updates related to Comprehensive Panel, Congenital Myopathy, Metabolic Myopathy, and Targeted Panel as items listed in revision summaries. These entries reflect additions and clarifications made in the policy history rather than new coverage criteria in this excerpt.[[78]][[87]]

Policy history also documents later summary entries that include Metabolic Myopathy and Targeted Panel among the items changed. These are listed in the Summary of Changes sections of the revision history.[[91]][[96]]

Policy History: several revision entries explicitly note removal of definitions. Notably, the policy history records removal of definitions for Comparative Genomic Hybridization (CGH) and Neuromuscular Disorders (NMD) in revision summaries.[[109]][[78]]

Policy History: removal of CPT codes is documented in multiple revision summaries. The entries explicitly state that CPT codes 0417U, 81440, 81460, and 81465 were removed from the Applicable Codes list.[[141]][[200]]

Policy History follow-up: later revision notes reiterate that CPT codes 0417U, 81440, 81460, and 81465 were removed from the policy’s applicable codes, appearing in multiple Policy History/Revision Information entries.[[159]][[254]]

Applicable Codes section in the policy history repeatedly notes removal of CPT codes 0417U, 81440, 81460, and 81465. These repeated entries indicate the codes were removed across several revision updates and should not be used for authorization or billing absent further policy change.[[200]][[204]]